Modality
Vaccine
MOA
WRNi
Target
EZH2
Pathway
Complement
Urothelial CaWilmsCLL
Development Pipeline
Preclinical
~Jun 2016
→ ~Sep 2017
Phase 1
~Dec 2017
→ ~Mar 2019
Phase 2
Jun 2019
→ Nov 2031
Phase 2Current
NCT08317469
954 pts·Urothelial Ca
2020-12→2031-11·Terminated
NCT07332824
1,490 pts·CLL
2019-06→2028-12·Active
2,444 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-12-142.7y awayPh2 Data· CLL
2031-11-095.6y awayPh2 Data· Urothelial Ca
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P2
Active
P2
Termina…
Catalysts
Ph2 Data
2028-12-14 · 2.7y away
CLL
Ph2 Data
2031-11-09 · 5.6y away
Urothelial Ca
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08317469 | Phase 2 | Urothelial Ca | Terminated | 954 | EFS |
| NCT07332824 | Phase 2 | CLL | Active | 1490 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| AMG-2752 | Amgen | Preclinical | MDM2 | |
| REG-7737 | Regeneron | Preclinical | CD123 | |
| VRT-5853 | Vertex Pharma | Phase 3 | Aβ | |
| Pemitapinarof | BeiGene | Approved | KRASG12C | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| VKT-4052 | Viking Therapeutics | Phase 2/3 | TNFα |